Growth hormone therapy before and after pediatric renal transplant

Area of Science:

• Pediatric Nephrology
• Endocrinology
• Transplantation Medicine

Background:

• Children with successful renal transplants aim for optimal growth and development.
• Recombinant human growth hormone (rhGH) use pre- and post-transplant (Tx) is supported by randomized controlled trials.
• Maximizing rhGH benefits requires comprehensive management strategies in renal patients.

Purpose of the Study:

• To evaluate the effectiveness of recombinant human growth hormone (rhGH) in pediatric renal transplant recipients.
• To identify strategies for optimizing growth and development in this population.
• To highlight areas for further research regarding rhGH's impact on renal allografts.

Main Methods:

• Review of randomized controlled trials evaluating rhGH in pediatric renal transplant recipients.
• Analysis of strategies to enhance rhGH efficacy, including nutritional support, bone parameter monitoring, and steroid reduction.
• Identification of knowledge gaps concerning rhGH's effects on renal allograft function and rejection.

Main Results:

• rhGH therapy has been evaluated and supported by randomized controlled trials for pediatric renal transplant recipients.
• Key strategies for maximizing rhGH benefits include adequate nutrition, bone health management, and reduced steroid therapy (e.g., alternate-day treatment).
• Further studies are needed to assess rhGH's impact on renal allograft function, rejection risk, and ultrastructural changes.

Conclusions:

• rhGH is a viable option for improving growth in children post-renal transplant.
• A multidisciplinary approach involving nutrition, bone health, and steroid management is crucial for successful rhGH therapy.
• More research is necessary to fully understand the long-term effects of rhGH on renal allograft outcomes.